EUVIMEDEUVIMED entdecken
Crossref

Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer

Anita Moein, Jin Y Jin, Matthew R Wright, Harvey Wong

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04690-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Anita Moein und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, The University of British Columbia, Office 5505, Pharmaceutical Sciences Building, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Fulvestrant, Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Receptors, Estrogen. Die Arbeit nennt 56 Literaturangaben. Gefördert von: This work was supported by Genentech Inc., a member of the Roche group..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FulvestrantClass I Phosphatidylinositol 3-KinasesBreast NeoplasmsReceptors, EstrogenAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesThiazolesPhosphoinositide-3 Kinase InhibitorsMutationHumansFemaleImidazolesOxazepinesNeoplasm MetastasisMiddle AgedEstradiolAgedLongitudinal Studies

Stichwörter der Autor:innen

Breast cancerCombination therapyFulvestrantPI3K inhibitorTumor growth inhibition

Substanzen

FulvestrantClass I Phosphatidylinositol 3-KinasesReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesThiazolesPhosphoinositide-3 Kinase InhibitorsImidazolesOxazepinesEstradiolPIK3CA protein, human

Autor:innen und Institutionen

  • Faculty of Pharmaceutical Sciences, The University of British Columbia, Office 5505, Pharmaceutical Sciences Building, Vancouver, BC, Canada.
  • Genentech, Inc., South San Francisco, CA, USA.
  • Faculty of Pharmaceutical Sciences, The University of British Columbia, Office 5505, Pharmaceutical Sciences Building, Vancouver, BC, Canada. harvey.wong@ubc.ca.

Förderung

  • This work was supported by Genentech Inc., a member of the Roche group.

Zitieren

APA

Moein, A., Jin, J. Y., Wright, M. R., & Wong, H. (2024). Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04690-4

Vancouver

Moein A, Jin JY, Wright MR, Wong H. Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04690-4

BibTeX
@article{Moein2024,
  author = {Moein, Anita and Jin, Jin Y and Wright, Matthew R and Wong, Harvey},
  title = {Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04690-4}
}
Kostenlos starten →